Chapter 2 · Financial Health
Lost $1.25B
in a year it sold
$606M of drugs.
Research and a national drug launch cost enormous money up front — long before the revenue catches up.
↓ scroll to read
✦ The bottom line
Insmed's 2025 operating loss was $1.25B — about double its revenue. The money goes to R&D (developing the next drugs) and launching Brinsupri (building a salesforce, educating doctors). It's funded by raising money from investors. As revenue ramps, the loss is already starting to narrow.
↓ the brief below
✦ Teach me
Why losing money can be the plan
In biotech, big losses aren't automatically bad — they're often the investment. Trials and launches cost hundreds of millions before a drug pays back. The company funds this by selling shares (and sometimes borrowing), betting the future drug profits will dwarf today's losses.
The risk is timing: if cash runs low before the drugs become profitable, the company must raise more — diluting owners — or stall. So you watch two things: is revenue ramping, and is there enough cash to reach profitability?
Wall Street calls this
Cash burn / runway
A biotech's losses tell you how aggressively it's investing; its *cash runway* tells you whether it can finish the job without a painful raise. Both matter more than this year's 'profit.'
Operating loss · fiscal year 2025
Roughly twice the year's revenue — the cost of R&D plus the Brinsupri launch. The most recent quarter's loss ($153M) is far smaller, a sign the revenue ramp is starting to close the gap.
Source · 10-K · Consolidated Statements of Operations · FY2025 · Filed Feb 19, 2026